Michael Barbella, Managing Editor05.12.22
NanoVibronix Inc.'s PainGuard and UroGuard devices have been approved by Health Canada/Santé Canada as licensed medical products.
The license issued by Health Canada allows Ideal Medical International Limited (Ideal Medical)—one of the company’s international distribution partners—to market and sell PainGuard and UroGuard as licensed medical devices in the country.
“This license clears the way for our distribution partner, Ideal Medical, to accelerate distribution of our products in Canada, another catalyst for our potential future growth and international expansion,” said Brian Murphy, CEO of NanoVibronix. “According to the Canadian Pain Task Force 1, nearly 8 million, or one in four Canadians aged 15 or older live with chronic pain. Our pain management products are safe and effective alternative treatment to prescription opioids, which have been the root cause of a number of unintended consequences including overdose and death. Similarly, there are millions of urinary catheters used in hospitals every year, and our urology products can serve as protection against urinary tract infections and the pain associated with the catheters. We are eager to serve the Canadian market through Ideal Medical and look forward to capitalizing on this new opportunity to drive further growth.”
NanoVibronix Inc. is a medical device company headquartered in Elmsford, N.Y., with research and development in Nesher, Israel that develops medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief. The company’s primary products are portable devices suitable for administration at home without assistance of medical professionals.
The license issued by Health Canada allows Ideal Medical International Limited (Ideal Medical)—one of the company’s international distribution partners—to market and sell PainGuard and UroGuard as licensed medical devices in the country.
“This license clears the way for our distribution partner, Ideal Medical, to accelerate distribution of our products in Canada, another catalyst for our potential future growth and international expansion,” said Brian Murphy, CEO of NanoVibronix. “According to the Canadian Pain Task Force 1, nearly 8 million, or one in four Canadians aged 15 or older live with chronic pain. Our pain management products are safe and effective alternative treatment to prescription opioids, which have been the root cause of a number of unintended consequences including overdose and death. Similarly, there are millions of urinary catheters used in hospitals every year, and our urology products can serve as protection against urinary tract infections and the pain associated with the catheters. We are eager to serve the Canadian market through Ideal Medical and look forward to capitalizing on this new opportunity to drive further growth.”
NanoVibronix Inc. is a medical device company headquartered in Elmsford, N.Y., with research and development in Nesher, Israel that develops medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief. The company’s primary products are portable devices suitable for administration at home without assistance of medical professionals.
